Profile data is unavailable for this security.
About the company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
- Revenue in USD (TTM)2.07m
- Net income in USD-47.68m
- Incorporated1988
- Employees76.00
- LocationDelcath Systems Inc566 Queensbury AvenueQUEENSBURY 12804United StatesUSA
- Phone+1 (518) 743-8892
- Fax+1 (212) 489-2102
- Websitehttps://delcath.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myomo Inc | 19.24m | -8.15m | 100.56m | 101.00 | -- | 10.66 | -- | 5.23 | -0.2726 | -0.2726 | 0.6265 | 0.3313 | 1.56 | 3.78 | 8.99 | 190,506.40 | -65.86 | -81.78 | -104.03 | -115.27 | 68.51 | 68.50 | -42.34 | -85.76 | 2.16 | -- | 0.00 | -- | 23.70 | 51.09 | 24.00 | -- | 2.82 | -- |
| KORU Medical Systems Inc | 28.52m | -13.74m | 102.85m | 82.00 | -- | 5.05 | -- | 3.61 | -0.3012 | -0.3012 | 0.6254 | 0.4457 | 0.8057 | 2.39 | 7.50 | 347,776.50 | -38.82 | -17.60 | -46.28 | -20.29 | 58.59 | 59.44 | -48.18 | -21.70 | 3.77 | -- | 0.0351 | -- | 2.23 | 10.44 | -58.65 | -- | 11.10 | -- |
| Neuronetics Inc | 71.35m | -30.19m | 106.56m | 203.00 | -- | 3.02 | -- | 1.49 | -1.06 | -1.06 | 2.49 | 1.18 | 0.6132 | 2.09 | 4.86 | 351,468.00 | -25.95 | -28.02 | -33.60 | -34.73 | 75.13 | 75.73 | -42.31 | -51.04 | 4.33 | -5.28 | 0.6342 | -- | 9.42 | 6.22 | 18.76 | -- | 18.57 | -- |
| Fonar Corp | 102.42m | 12.16m | 107.43m | 561.00 | 9.18 | 0.6556 | 5.17 | 1.05 | 1.74 | 1.74 | 14.60 | 24.42 | 0.5124 | 20.35 | 1.44 | 182,570.60 | 8.33 | 8.73 | 8.64 | 9.60 | 45.67 | 48.33 | 16.25 | 16.39 | 9.15 | -- | 0.0055 | -- | 1.08 | 3.89 | -24.71 | -15.05 | 8.48 | -- |
| Xtant Medical Holdings Inc | 91.30m | 660.00k | 112.12m | 207.00 | -- | 2.18 | 29.24 | 1.23 | -0.0042 | -0.0042 | 0.755 | 0.3945 | 1.19 | 1.32 | 5.78 | 441,072.50 | 0.8636 | -10.38 | 1.15 | -14.68 | 60.75 | 61.08 | 0.7229 | -8.66 | 1.22 | -4.02 | 0.2997 | -- | 57.50 | 4.81 | 107.78 | -- | 18.47 | -- |
| TELA Bio Inc | 58.45m | -46.66m | 114.15m | 227.00 | -- | 6.01 | -- | 1.95 | -2.06 | -2.06 | 2.56 | 0.7708 | 0.8013 | 1.47 | 7.15 | 257,502.20 | -63.97 | -52.00 | -80.09 | -60.95 | 68.62 | 65.32 | -79.83 | -107.65 | 3.45 | -8.44 | 0.6821 | -- | 41.13 | 47.85 | -5.35 | -- | -17.12 | -- |
| Akso Health Group - ADR | 2.20m | -17.07m | 124.67m | 12.00 | -- | -- | -- | 56.60 | -0.7466 | -0.2461 | 0.0963 | -- | 0.1166 | 1.91 | 0.3202 | 183,560.00 | -89.84 | -17.36 | -224.28 | -23.99 | 7.56 | -- | -770.59 | -256.64 | 1.36 | -24.02 | 0.6531 | -- | 119.69 | -34.25 | -221.68 | -- | -- | -- |
| Delcath Systems Inc | 2.07m | -47.68m | 137.37m | 76.00 | -- | 7.79 | -- | 66.52 | -2.98 | -2.98 | 0.1273 | 0.6931 | 0.0731 | 0.2387 | 6.80 | 27,171.05 | -168.85 | -116.57 | -377.02 | -243.21 | 69.25 | 71.02 | -2,308.86 | -1,235.37 | 2.06 | -26.53 | 0.3915 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
| Clearpoint Neuro Inc | 23.96m | -22.09m | 146.72m | 107.00 | -- | 6.31 | -- | 6.12 | -0.8979 | -0.8979 | 0.9736 | 0.8589 | 0.4881 | 1.20 | 8.15 | 223,878.50 | -45.01 | -34.75 | -52.63 | -39.67 | 56.83 | 64.75 | -92.21 | -76.91 | 3.80 | -- | 0.3197 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Outset Medical Inc | 130.38m | -172.80m | 147.35m | 480.00 | -- | 1.17 | -- | 1.13 | -3.49 | -3.49 | 2.64 | 2.44 | 0.3652 | 2.01 | 4.27 | 271,616.70 | -48.41 | -41.40 | -56.97 | -47.29 | 22.24 | 5.71 | -132.54 | -159.05 | 4.37 | -67.80 | 0.5143 | -- | 13.00 | 130.43 | -6.04 | -- | 14.27 | -- |
| Electromed Inc | 51.69m | 3.94m | 151.88m | 170.00 | 39.24 | 3.76 | 32.63 | 2.94 | 0.4498 | 0.4498 | 5.91 | 4.69 | 1.17 | 2.95 | 2.27 | 304,076.50 | 8.91 | 7.86 | 10.39 | 9.14 | 76.51 | 76.25 | 7.62 | 7.38 | 5.25 | -- | 0.00 | 0.00 | 15.38 | 11.17 | 37.35 | 11.00 | 24.58 | -- |
| Orchestra Biomed Holdings Inc | 2.76m | -49.12m | 157.42m | 56.00 | -- | 2.31 | -- | 57.04 | -1.49 | -1.49 | 0.0832 | 1.90 | 0.0289 | 0.8815 | 28.31 | 49,285.71 | -51.49 | -- | -61.01 | -- | 93.26 | -- | -1,779.71 | -- | 7.94 | -- | 0.00 | -- | -21.88 | -- | -37.91 | -- | -- | -- |
| InfuSystem Holdings Inc | 125.79m | 872.00k | 165.44m | 499.00 | 196.32 | 3.15 | 12.32 | 1.32 | 0.0396 | 0.0396 | 5.86 | 2.47 | 1.24 | 11.17 | 6.85 | 252,074.10 | 0.8621 | 4.60 | 1.01 | 5.69 | 50.17 | 56.43 | 0.6933 | 4.07 | 1.54 | 1.88 | 0.3575 | 0.00 | 14.44 | 13.38 | 4,744.44 | -- | 6.01 | -- |
| Butterfly Network Inc | 65.90m | -133.70m | 165.81m | 225.00 | -- | 0.7426 | -- | 2.52 | -0.6507 | -0.6507 | 0.3209 | 1.06 | 0.1826 | 0.7376 | 4.69 | 292,888.90 | -37.04 | -- | -42.70 | -- | 25.58 | -- | -202.88 | -- | 3.57 | -- | 0.00 | -- | -10.21 | -- | 20.76 | -- | -- | -- |
| Inogen Inc | 315.66m | -102.45m | 166.01m | 834.00 | -- | 0.8029 | -- | 0.5259 | -4.42 | -4.42 | 13.62 | 8.78 | 0.8634 | 6.76 | 6.01 | 378,489.20 | -28.02 | -8.23 | -34.53 | -9.53 | 40.14 | 44.54 | -32.46 | -10.31 | 2.56 | -- | 0.00 | -- | -16.32 | -2.49 | -22.30 | -- | 26.34 | -- |
Data as of May 02 2024. Currency figures normalised to Delcath Systems Inc's reporting currency: US Dollar USD
23.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Dec 2023 | 1.18m | 5.36% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.04m | 4.71% |
| BVF Partners LPas of 31 Dec 2023 | 976.15k | 4.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 519.13k | 2.36% |
| Logos Global Management LPas of 31 Dec 2023 | 300.00k | 1.36% |
| Worth Venture Partners LLCas of 31 Dec 2023 | 294.25k | 1.34% |
| CIBC World Markets, Inc.as of 31 Dec 2023 | 261.43k | 1.19% |
| Adar1 Capital Management LLCas of 31 Dec 2023 | 231.30k | 1.05% |
| Geode Capital Management LLCas of 31 Dec 2023 | 169.60k | 0.77% |
| Hunting Hill Global Capital LLCas of 31 Dec 2023 | 164.85k | 0.75% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
